X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (3) 3
female (3) 3
humans (3) 3
middle aged (3) 3
oncology (3) 3
adult (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
chemotherapy, adjuvant (2) 2
disease-free survival (2) 2
fluorouracil (2) 2
follow-up studies (2) 2
index medicus (2) 2
male (2) 2
neoplasm staging (2) 2
5-fluorouracil (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
adjuvant chemotherapy (1) 1
advanced gastric-cancer (1) 1
advanced solid tumors (1) 1
anthracyclines - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - therapeutic use (1) 1
bevacizumab (1) 1
boronic acids - therapeutic use (1) 1
bortezomib (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - pathology (1) 1
cancer (1) 1
carboplatin (1) 1
carcinoma (1) 1
carcinoma, ductal, breast - drug therapy (1) 1
carcinoma, ductal, breast - pathology (1) 1
carcinoma, large cell - drug therapy (1) 1
carcinoma, large cell - mortality (1) 1
carcinoma, large cell - pathology (1) 1
carcinoma, lobular - drug therapy (1) 1
carcinoma, lobular - pathology (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
carcinoma, squamous cell - drug therapy (1) 1
carcinoma, squamous cell - mortality (1) 1
carcinoma, squamous cell - pathology (1) 1
cardia (1) 1
care and treatment (1) 1
chemotherapy (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
cisplatin plus gemcitabine (1) 1
cmf (1) 1
combination (1) 1
combined modality therapy (1) 1
cyclophosphamide (1) 1
drug administration schedule (1) 1
epirubicin (1) 1
esophageal (1) 1
esophageal neoplasms - drug therapy (1) 1
esophageal neoplasms - mortality (1) 1
esophageal neoplasms - surgery (1) 1
esophagogastric junction (1) 1
fluorouracil - administration & dosage (1) 1
frontline (1) 1
hematology, oncology and palliative medicine (1) 1
i trial (1) 1
inhibitors (1) 1
junction (1) 1
locally advanced cancer (1) 1
lung cancer, non-small cell (1) 1
lung neoplasms - drug therapy (1) 1
lung neoplasms - mortality (1) 1
lung neoplasms - pathology (1) 1
lymphatic metastasis (1) 1
malignancies (1) 1
mastectomy, modified radical (1) 1
mastectomy, segmental (1) 1
maximum tolerated dose (1) 1
medical research (1) 1
medicine, experimental (1) 1
methotrexate (1) 1
neoadjuvant chemotherapy (1) 1
neoplasm grading (1) 1
neoplasm recurrence, local - drug therapy (1) 1
neoplasm recurrence, local - mortality (1) 1
neoplasm recurrence, local - pathology (1) 1
neoplasm recurrence, local - prevention & control (1) 1
neoplastic cells, circulating - pathology (1) 1
non-small cell lung cancer (1) 1
oncology, experimental (1) 1
oxaliplatin (1) 1
paclitaxel (1) 1
perioperative period (1) 1
phase ii (1) 1
postmenopausal patients (1) 1
postmenopause - drug effects (1) 1
prognosis (1) 1
pulmonary/respiratory (1) 1
pyrazines - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 2011, Volume 76, Issue 1, pp. 78 - 83
Abstract Background Preliminary results indicated that bortezomib (B) (Velcade*) as a single agent may have activity in pretreated NSCLC patients with similar... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Phase II | Bortezomib | Non-small cell lung cancer | Frontline | ADJUVANT CHEMOTHERAPY | CARBOPLATIN | ADVANCED SOLID TUMORS | BEVACIZUMAB | COMBINATION | PACLITAXEL | CISPLATIN PLUS GEMCITABINE | ONCOLOGY | RESPIRATORY SYSTEM | I TRIAL | MALIGNANCIES | INHIBITORS | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Neoplastic Cells, Circulating - pathology | Lung Neoplasms - mortality | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Large Cell - mortality | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Carcinoma, Squamous Cell - mortality | Neoplasm Grading | Female | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Adenocarcinoma - mortality | Antimitotic agents | Medical research | Care and treatment | Chemotherapy | Oncology, Experimental | Medicine, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Acta Oncologica, ISSN 0284-186X, 2005, Volume 44, Issue 5, pp. 458 - 466
Two randomized trials evaluated the effect of 6 courses of anthracycline-based chemotherapy in early breast cancer. A total of 1 146 patients were included:... 
WOMEN | 5-FLUOROURACIL | THERAPY | EPIRUBICIN | ONCOLOGY | CYCLOPHOSPHAMIDE | TAMOXIFEN | METHOTREXATE | FLUOROURACIL | CMF | POSTMENOPAUSAL PATIENTS
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.